Rate of development of clinical definite multiple sclerosis 10 years [clinicaltrials_resource:78a27e02fdfeea0f636f260b91b605b1]
Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Rate of development of clinical definite multiple sclerosis 10 years [clinicaltrials_resource:78a27e02fdfeea0f636f260b91b605b1]
Initiation of treatment with Interferon Beta 1a IM once weekly immediately after onset of a first demyelinating syndrome in high risk individuals
Bio2RDF identifier
78a27e02fdfeea0f636f260b91b605b1
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:78a27e02fdfeea0f636f260b91b605b1
measure [clinicaltrials_vocabulary:measure]
Rate of development of clinical definite multiple sclerosis
time frame [clinicaltrials_vocabulary:time-frame]
description
Initiation of treatment with I ...... drome in high risk individuals
identifier
clinicaltrials_resource:78a27e02fdfeea0f636f260b91b605b1
title
Rate of development of clinical definite multiple sclerosis 10 years
@en
type
label
Rate of development of clinica ...... 27e02fdfeea0f636f260b91b605b1]
@en